Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 24, No 22 (August 1), 2006: pp. 3576-3582
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.05.1896

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Madalinska, J. B.
Right arrow Articles by Aaronson, N. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Madalinska, J. B.
Right arrow Articles by Aaronson, N. K.
Related Articles
Right arrowRelated Editorial

The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy

Joanna B. Madalinska, Marc van Beurden, Eveline M.A. Bleiker, Heiddis B. Valdimarsdottir, Judith Hollenstein, Leon F. Massuger, Katja N. Gaarenstroom, Marian J.E. Mourits, René H.M. Verheijen, Eleonora B.L. van Dorst, Hans van der Putten, Ko van der Velden, Henk Boonstra, Neil K. Aaronson

From the Division of Psychosocial Research and Epidemiology, and Department of Gynecology, the Netherlands Cancer Institute; Department of Gynecology, Vrije Universiteit University Medical Center; Department of Gynecology, Academic Medical Center, Amsterdam; Department of Gynecology, University Medical Center Nijmegen, Nijmegen; Department of Gynecology, Leiden University Medical Center, Leiden; Department of Gynecology, University Medical Center Groningen, University of Groningen; Department of Gynecology, University Medical Center Utrecht, Utrecht; Department of Gynecology, Academic Hospital Maastricht, Maastricht, the Netherlands; and Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY

Address reprint requests to Neil K. Aaronson, PhD, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Division of Psychosocial Research and Epidemiology, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; e-mail: n.aaronson{at}nki.nl

PURPOSE: Preventive health strategies for women at increased hereditary risk of ovarian cancer include gynecologic screening (GS) and/or prophylactic oophorectomy (PBSO). Hormone replacement therapy (HRT) is often prescribed to compensate for postsurgical endocrine deficiencies. This study examined the impact of HRT use on levels of endocrine symptoms and sexual functioning among premenopausal women who have undergone PBSO. Comparisons were made with similar women undergoing GS.

PATIENTS AND METHODS: Questionnaire data on endocrine symptoms and sexual functioning were obtained from 450 premenopausal, high-risk women who had participated in this nationwide, cross-sectional, observational study.

RESULTS: Thirty-six percent of women had undergone PBSO and 64% had opted for GS. In the PBSO group, 47% of the women were current HRT users. They reported significantly fewer vasomotor symptoms than nonusers (P < .05). However, compared with premenopausal women undergoing GS, oophorectomized HRT users were more likely to report vasomotor symptoms (P < .01). HRT users and nonusers reported comparable levels of sexual functioning. Compared with women in the GS group, oophorectomized HRT users reported significantly more sexual discomfort due to vaginal dryness and dyspareunia (P < .01).

CONCLUSION: Although HRT has a positive impact on surgically induced vasomotor symptoms, it may be less effective than is often assumed. Symptom levels remain well above those of premenopausal women undergoing screening, and sexual discomfort is not alleviated by HRT. Physicians need to provide younger high-risk women considering PBSO with realistic information about both benefits and drawbacks of this preventive strategy, including information about premature menopause and HRT.

Supported by Grant No. NKI 2001-2382 from the Dutch Cancer Society.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Editorial

  • Is the Fault in Our Steroids or in Our Selves?
    Leslie R. Schover
    JCO 2006 24: 3519-3521 [Full Text]


This article has been cited by other articles:


Home page
Ann OncolHome page
M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, and V. Stearns
Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer
Ann. Onc., June 16, 2008; (2008) mdn353v2.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. B. Madalinska, M. van Beurden, E. M.A. Bleiker, H. B. Valdimarsdottir, L. Lubsen-Brandsma, L. F. Massuger, M. J.E. Mourits, K. N. Gaarenstroom, E. B.L. van Dorst, H. van der Putten, et al.
Predictors of Prophylactic Bilateral Salpingo-Oophorectomy Compared With Gynecologic Screening Use in BRCA1/2 Mutation Carriers
J. Clin. Oncol., January 20, 2007; 25(3): 301 - 307.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. R. Schover
Is the Fault in Our Steroids or in Our Selves?
J. Clin. Oncol., August 1, 2006; 24(22): 3519 - 3521.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online